HALIFAX, June 29 /PRNewswire-FirstCall/ - MedMira Inc., ("MedMira")
(TSX Venture: MIR, NASDAQ: MMIRF) a global market leader in premium rapid
diagnostic solutions, announced today that it has expanded its global sales
team in order to capitalize on market penetration opportunities from
recently completed key regulatory approvals.
The expansion includes two new regional account managers dedicated to
the Europe/Middle East and Latin America markets. Jaime Carreno and Pierre
Sevigny together bring over 25 years of experience selling medical and
technical products in these markets to the MedMira team.
"We are very pleased to have these individuals on board and dedicated
to leveraging sales opportunities in these important regions," said Hermes
Chan, President & COO, MedMira Inc. "Ramping up our sales capabilities will
enable us to better meet the needs of distributors and customers in
critical global markets, like Latin America and Europe."
After receiving CE Mark in early 2006 for its MiraCare(TM) Rapid HIV
Antibody Test (MiraCare HIV), MedMira strategically selected countries in
which to register with the Competent Authority, governing bodies within
each member country regulating the sale of medical devices. MedMira's
Regulatory Team has completed 13 registrations, the final step in the
regulatory process, and will continue to pursue registrations in strategic
country markets where sales opportunities exist.
In Asia, MedMira has engaged MediServe Inc., a leading consulting group
to head-up the company's sales and marketing activities in that region.
MediServe is a partnership of project managers, medical doctors and
healthcare practitioners, each with over 10 years of marketing and
healthcare experience in Asia. The partners have a strong track record of
serving international players such as Merck and their strengths include
sales and distribution channel management and outsourcing business
projects. MediServe was on-site at MedMira corporate headquarters in
Halifax early this month to receive in-depth product training and finalize
plans to launch MedMira's recently approved whole blood rapid HIV test in
China. In April 2006, MedMira received a fast- tracked approval for the
first and only whole blood rapid HIV test available in China. This approval
enables MediServe to quickly capitalize on a key competitive advantage for
MedMira in the China market.
"With this latest whole blood approval and our new on-the-ground sales
and marketing team in place, the timing is right to create a unique niche
market for MedMira in China," said Chan. "We will also turn our attention
to increasing MedMira's presence in developing nations, becoming part of
their large scale testing programs."
Richard Van Maanen, a biotechnology consultant and a former sales and
marketing executive with another leading diagnostics manufacturer has been
engaged by MedMira. Mr. Van Maanen will focus on increasing MedMira's
profile with the international agencies and non-government organizations
(NGOs) that provide testing solutions and programs to Africa and other
developing nations. He will also identify qualified distributors and
initiate local product registrations for MedMira in the Sub-Saharan region.
MedMira's new sales & marketing team members will be travelling to
various countries in their respective territories in the coming months,
seeking new distributors in untapped markets, managing distributor
relationships and capitalizing on sales opportunities for MedMira products.
Additionally, MedMira will be taking part in the American Association for
Clinical Chemistry's Clinical Lab Expo, July 25-27 in Chicago and the XVI
International AIDS Conference (AIDS 2006) in Toronto, August 13-18. AIDS
2006 is a biennial conference that draws members of the international
scientific, political, and business communities together to discuss and
develop strategies to fight HIV/AIDS.
On the regulatory front, MedMira continues preparations to enter the US
market with an over-the-counter (OTC) rapid HIV test. MedMira has submitted
a proposed solution to the FDA and is ready to begin the market entry and
regulatory process once the proposal is reviewed. MedMira's proposed US OTC
solution is built on the company's solid experience in the Hong Kong OTC
market, where it successfully launched its MiraCare HIV test in 2005.
MedMira is the leading global manufacturer and marketer of in vitro
flow- through rapid diagnostic tests. MedMira's tests provide reliable,
rapid diagnosis in just 3 minutes for the detection of human antibodies in
human serum, plasma or whole blood for diseases such as HIV and hepatitis
C. The United States FDA, the SFDA in the People's Republic of China and
European Union have approved MedMira's Reveal(R) G2, MiraWell(R) and
MiraCare(TM) rapid HIV tests, respectively.
MedMira's Reveal(R) G2 and MiraWell(R) rapid HIV tests are currently
used in clinical laboratories, hospitals, and clinics where professional
counselling and patient treatment are immediately available.
MiraCare(TM) is sold through MedMira's distributor network to
pharmacies, hospitals and laboratories in the European Union. It is also
available over- the-counter (OTC) in pharmacies throughout Hong Kong and
Macao Special Administrative Regions, in the People's Republic of China.
MedMira delivers rapid diagnostic solutions to healthcare communities
around the globe. Its corporate offices and manufacturing facilities are
located in Halifax, Nova Scotia, Canada with a representative office and
joint venture manufacturing facility in Guilin, China.
This news release contains forward-looking statements, which involve
risk and uncertainties and reflect the company's current expectation
regarding future events. Actual events could materially differ from those
projected herein and depend on a number of factors including, but not
limited to, changing market conditions, successful and timely completion of
clinical studies, uncertainties related to the regulatory approval process,
establishment of corporate alliances and other risks detailed from time to
time in the company quarterly filings.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this statement.
For more information visit MedMira's website at www.medmira.com.
SOURCE MedMira Inc.